A compounded semaglutide offer may look similar to a branded medicine advertisement. It can use the same ingredient name and promise an easy online process. But the regulatory status and the evidence for the finished preparation are different.
Understanding those differences does not require becoming a pharmacist. It starts with a few direct questions about why compounding is proposed, what is in the prescription, and how current requirements apply to it.
One thing to keep with you
Compounded semaglutide is not an FDA-approved generic, and a low price does not establish an appropriate reason for compounding.
What FDA approval does not transfer to
FDA-approved products have undergone the agency’s review for their labeled uses. Compounded drugs do not undergo that same premarket review for safety, effectiveness, and quality. A clinical trial of an approved product should not be presented as a trial of every preparation using the ingredient name.
FDA recommends compounded GLP-1 drugs only for patients whose medical needs cannot be met by an approved medicine. Ask the prescriber to explain the specific need, rather than assuming the compounded option is simply the normal lower-cost generic.
Checked with: FDA: compounding questions and answers · FDA: concerns about unapproved GLP-1 products
The old shortage is not a current permission slip
FDA determined the shortage of semaglutide injection products was resolved in February 2025 and described the transition in compounding enforcement policy. The present situation cannot be understood by repeating an advertisement from the shortage period.
Individual compounding circumstances and legal requirements need current, qualified review. Adding another ingredient does not automatically make a product exempt from restrictions on copies. Our CoreAge review applies this distinction to the advertised offer rather than declaring a blanket right to supply it.
Checked with: FDA: compounding policy after supply stabilization · CoreAge Rx: semaglutide offer
Ask what the ingredient actually is
FDA has warned that semaglutide sodium and semaglutide acetate are different active ingredients from the form used in approved drugs, and it has not identified a lawful basis for using those salts in compounding. Do not assume a similar name means the same reviewed product.
Ask for the exact formulation and dispensing pharmacy. Verify licensing and obtain clear storage, shipment, and use instructions. The basic semaglutide guide explains why the ingredient, product, and care service are separate pieces of information.
Checked with: FDA: concerns about unapproved GLP-1 products · FDA: checking online pharmacies
Measurement mistakes can be serious
FDA has received reports of dosing errors involving compounded injectable semaglutide, including events requiring hospitalization. Vial concentration, prescribed milligrams, liquid volume, and syringe markings can be confused. There is no universal number of syringe units that applies to every vial.
If the instructions are unclear, contact the pharmacist or prescriber before using the medication. Read the safety guide and compare approved-product access as part of the conversation. This page does not certify a pharmacy or determine whether a particular compounded prescription meets current requirements.
Checked with: FDA: compounded semaglutide dosing errors · NovoCare: Wegovy pharmacy offer
Where we checked the facts
- FDA: compounding questions and answers
Compounded drugs are not FDA-approved.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
- FDA: compounding policy after supply stabilization
Semaglutide injection shortage resolved in February 2025. Old shortage exemptions do not establish unrestricted present-day access.
- CoreAge Rx: semaglutide offer
Commercial compounded-product offer, starting at $99/month when checked September 23, 2026. Not an FDA-approved generic or proof of comparative outcomes.
- FDA: checking online pharmacies
Use official licensing and pharmacy checks; a review site is not a pharmacy auditor.
- FDA: compounded semaglutide dosing errors
Reports involving measurement and conversion errors, including hospitalizations; no universal syringe-unit conversion is appropriate.
- NovoCare: Wegovy pharmacy offer
Manufacturer access and pricing terms checked September 23, 2026. Formulation, strength, eligibility and offer period affect cost.
